Aldara

国家: 欧盟

语言: 英文

来源: EMA (European Medicines Agency)

现在购买

资料单张 资料单张 (PIL)
01-03-2024
产品特点 产品特点 (SPC)
01-03-2024
公众评估报告 公众评估报告 (PAR)
08-10-2008

有效成分:

imiquimod

可用日期:

Viatris Healthcare Limited

ATC代码:

D06BB10

INN(国际名称):

imiquimod

治疗组:

Antibiotics and chemotherapeutics for dermatological use

治疗领域:

Condylomata Acuminata; Keratosis; Keratosis, Actinic; Carcinoma, Basal Cell

疗效迹象:

Imiquimod cream is indicated for the topical treatment of :External genital and perianal warts (condylomata acuminata) in adults.Small superficial basal cell carcinomas (sBCCs) in adults.Clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses (AKs) on the face or scalp in immunocompetent adult patients when size or number of lesions limit the efficacy and/or acceptability of cryotherapy and other topical treatment options are contraindicated or less appropriate.

產品總結:

Revision: 31

授权状态:

Authorised

授权日期:

1998-09-18

资料单张

                                24
B. PACKAGE LEAFLET
25
PACKAGE LEAFLET: INFORMATION FOR THE USER
ALDARA 5% CREAM
IMIQUIMOD
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, please ask your doctor or your
pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If any get any side effects talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1. What Aldara cream is and what it is used for
2. What you need to know before you use Aldara cream
3. How to use Aldara cream
4. Possible side effects
5. How to store Aldara cream
6. Contents of the pack and other information
1.
WHAT ALDARA CREAM IS AND WHAT IT IS USED FOR
Aldara cream may be used for three different conditions. Your doctor
may prescribe Aldara cream for
the treatment of:
•
Warts (condylomata acuminata) on the surface of the genitals (sexual
organs) and around the
anus (back passage)
•
Superficial basal cell carcinoma.
This is a common slow-growing form of skin cancer with a very small
likelihood of spread to
other parts of the body. It usually occurs in middle-aged and elderly
people, especially those
who are fair-skinned and is caused by too much sun exposure. If left
untreated, basal cell
carcinoma can disfigure, especially on the face – therefore early
recognition and treatment are
important.
•
Actinic keratosis
Actinic keratoses are rough areas of skin found in people who have
been exposed to a lot of
sunshine over the course of their lifetime. Some are skin coloured,
others are greyish, pink,
red or brown. They can be flat and scaly, or raised, rough, hard and
warty. Aldara should only
be used for flat actinic keratoses on the face and scalp in patients
with a healthy immune
system where your doctor has decided that Aldara
                                
                                阅读完整的文件
                                
                            

产品特点

                                1
_ _
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
ALDARA 5% cream
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
_ _
Each sachet contains 12.5 mg of imiquimod in 250 mg cream (5 %).
100 mg of cream contains 5 mg of imiquimod.
Excipients with known effects:
Methyl hydroxybenzoate (E 218) 2.0 mg/g cream
Propyl hydroxybenzoate (E 216) 0.2 mg/g cream
Cetyl alcohol 22.0 mg/g cream
Stearyl alcohol 31.0 mg/g cream
Benzyl alcohol 20.0 mg/g cream
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Cream.
White to slightly yellow cream.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Imiquimod cream is indicated for the topical treatment of:
•
External genital and perianal warts (condylomata acuminata) in adults.
•
Small superficial basal cell carcinomas (sBCCs) in adults.
•
Clinically typical, nonhyperkeratotic, nonhypertrophic actinic
keratoses (AKs) on the face or
scalp in immunocompetent adult patients when size or number of lesions
limit the efficacy
and/or acceptability of cryotherapy and other topical treatment
options are contraindicated or
less appropriate.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
The application frequency and duration of treatment with imiquimod
cream is different for each
indication.
External genital warts in adults:
Imiquimod cream should be applied 3 times per week (example: Monday,
Wednesday, and Friday; or
Tuesday, Thursday, and Saturday) prior to normal sleeping hours, and
should remain on the skin for
6 to 10 hours. Imiquimod cream treatment should continue until the
clearance of visible genital or
_ _
perianal warts or for a maximum of 16 weeks per episode of warts.
For quantity to be applied see section 4.2 Method of administration.
_ _
3
Superficial basal cell carcinoma in adults:
Apply imiquimod cream for 6 weeks, 5 times per week (example: Monday
to Friday) prior to normal
sleeping hours, and leave on the skin for approximately 8 hours.
For quantity to be applied see 4.2 Method of administration.
Actinic keratosis
                                
                                阅读完整的文件
                                
                            

其他语言的文件

资料单张 资料单张 保加利亚文 01-03-2024
产品特点 产品特点 保加利亚文 01-03-2024
公众评估报告 公众评估报告 保加利亚文 08-10-2008
资料单张 资料单张 西班牙文 01-03-2024
产品特点 产品特点 西班牙文 01-03-2024
公众评估报告 公众评估报告 西班牙文 08-10-2008
资料单张 资料单张 捷克文 01-03-2024
产品特点 产品特点 捷克文 01-03-2024
公众评估报告 公众评估报告 捷克文 08-10-2008
资料单张 资料单张 丹麦文 01-03-2024
产品特点 产品特点 丹麦文 01-03-2024
公众评估报告 公众评估报告 丹麦文 08-10-2008
资料单张 资料单张 德文 01-03-2024
产品特点 产品特点 德文 01-03-2024
公众评估报告 公众评估报告 德文 08-10-2008
资料单张 资料单张 爱沙尼亚文 01-03-2024
产品特点 产品特点 爱沙尼亚文 01-03-2024
公众评估报告 公众评估报告 爱沙尼亚文 08-10-2008
资料单张 资料单张 希腊文 01-03-2024
产品特点 产品特点 希腊文 01-03-2024
公众评估报告 公众评估报告 希腊文 08-10-2008
资料单张 资料单张 法文 01-03-2024
产品特点 产品特点 法文 01-03-2024
公众评估报告 公众评估报告 法文 08-10-2008
资料单张 资料单张 意大利文 01-03-2024
产品特点 产品特点 意大利文 01-03-2024
公众评估报告 公众评估报告 意大利文 08-10-2008
资料单张 资料单张 拉脱维亚文 01-03-2024
产品特点 产品特点 拉脱维亚文 01-03-2024
公众评估报告 公众评估报告 拉脱维亚文 08-10-2008
资料单张 资料单张 立陶宛文 01-03-2024
产品特点 产品特点 立陶宛文 01-03-2024
公众评估报告 公众评估报告 立陶宛文 08-10-2008
资料单张 资料单张 匈牙利文 01-03-2024
产品特点 产品特点 匈牙利文 01-03-2024
公众评估报告 公众评估报告 匈牙利文 08-10-2008
资料单张 资料单张 马耳他文 01-03-2024
产品特点 产品特点 马耳他文 01-03-2024
公众评估报告 公众评估报告 马耳他文 08-10-2008
资料单张 资料单张 荷兰文 01-03-2024
产品特点 产品特点 荷兰文 01-03-2024
公众评估报告 公众评估报告 荷兰文 08-10-2008
资料单张 资料单张 波兰文 01-03-2024
产品特点 产品特点 波兰文 01-03-2024
公众评估报告 公众评估报告 波兰文 08-10-2008
资料单张 资料单张 葡萄牙文 01-03-2024
产品特点 产品特点 葡萄牙文 01-03-2024
公众评估报告 公众评估报告 葡萄牙文 08-10-2008
资料单张 资料单张 罗马尼亚文 01-03-2024
产品特点 产品特点 罗马尼亚文 01-03-2024
公众评估报告 公众评估报告 罗马尼亚文 08-10-2008
资料单张 资料单张 斯洛伐克文 01-03-2024
产品特点 产品特点 斯洛伐克文 01-03-2024
公众评估报告 公众评估报告 斯洛伐克文 08-10-2008
资料单张 资料单张 斯洛文尼亚文 01-03-2024
产品特点 产品特点 斯洛文尼亚文 01-03-2024
公众评估报告 公众评估报告 斯洛文尼亚文 08-10-2008
资料单张 资料单张 芬兰文 01-03-2024
产品特点 产品特点 芬兰文 01-03-2024
公众评估报告 公众评估报告 芬兰文 08-10-2008
资料单张 资料单张 瑞典文 01-03-2024
产品特点 产品特点 瑞典文 01-03-2024
公众评估报告 公众评估报告 瑞典文 08-10-2008
资料单张 资料单张 挪威文 01-03-2024
产品特点 产品特点 挪威文 01-03-2024
资料单张 资料单张 冰岛文 01-03-2024
产品特点 产品特点 冰岛文 01-03-2024
资料单张 资料单张 克罗地亚文 01-03-2024
产品特点 产品特点 克罗地亚文 01-03-2024

搜索与此产品相关的警报

查看文件历史